Schrodinger, Inc. (SDGR): Cost of Revenue
$113.25M
Year ended 2025-12-31
$111.72M
Trailing 12 months to 2026-06-30
+12.3%
3-year compound annual growth
+20.5%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $113.25M | +50.1% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $75.46M | -0.7% | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | $75.97M | -5.0% | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | $79.93M | +10.5% | 2025-02-26, From 2022-01-01 |
| 2021-12-31 | $72.31M | +62.0% | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | $44.62M | +22.4% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $36.45M | n/a | 2022-02-24, From 2019-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $113.25M | +50.1% |
| Harrow, Inc. (HROW) | 2025-12-31 | $67.93M | +38.0% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $39.46M | -37.5% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $58.16M | -9.7% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $100.07M | +19.2% |
| CorMedix Inc. (CRMD) | 2025-12-31 | $22.09M | +628.0% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $19.49M | +45.8% |
| MannKind Corp (MNKD) | 2025-12-31 | $26.80M | +53.8% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $151.75M | +0.6% |
Compare SDGR, HROW, AKBA, PBYI side by side · Screen every company in Pharmaceutical Preparations ↗